SECURGIN ® is a drug based on ethinyl estradiol + desogestrel
THERAPEUTIC GROUP: Systemic hormonal contraceptives - Progestin and estrogen, fixed combination
Indications SECURGIN ® - Contraceptive Pill
SECURGIN® is used as an oral contraceptive.
Mechanism of action SECURGIN ® - Contraceptive Pill
The contraceptive action of SECURGIN ® is guaranteed by the presence of ethinyl estradiol and desogestrel at such concentrations as to induce both central and local effects.
More precisely, the aforementioned hormones are able to inhibit the pituitary secretion of gonadotropins, FSH and LH, thus interfering with the processes of oocyte maturation and with ovulation itself, and at the same time inducing chemical-physical changes in the cervical mucus such as to counteract the ascent of the spermatozoa in the female genital tract and the possible nesting of the embryo in the uterine mucosa.
The estrogens contained in SECURGIN ® allow to classify this medicine among the third generation oral contraceptives, which were born with the intent to reduce some side effects such as weight gain and skin disorders have unfortunately been associated with an increased risk of developing thromboembolic events.
Studies carried out and clinical efficacy
1. DESOGESTREL-BASED CONTRACETIVES AND LDL METABOLISM
Contraception. 2011 Aug; 84: 160-8. Epub 2011 Jan 28.
Effect of a combination oral contraceptive (desogestrel + ethinyl estradiol) on the expression of low-density lipoprotein receptor and its transcription factor (SREBP2) in placental trophoblast cells.
Arjuman A, Pandey H, Chandra NC.
Very interesting in vitro study that demonstrates how oral contraceptives based on ethinylestradiol and desogestrel are able to induce the expression of LDL receptors in placental trophoblast cells. This study could partly justify the effects of desogestrel on lipid metabolism observed in vivo. .
2. EFFECTS OF DESOGESTREL ON THE MICROCIRCLE
Microcirculation. 2011 Jul; 18: 339-46.
Combined oral contraceptive pills containing desogestrel or drospirenone enhance large vessel and microvasculature vasodilation in healthy premenopausal women.
Thompson AK, Przemska A, Vasilopoulou D, Newens KJ, Williams CM.
Study that demonstrates how contraceptives based on desogesterl and ethinylestradiol can induce an endothelium-dependent vasodilation thanks to the differential expression of eNOS, which produces nitric oxide. This action seems to be mediated above all by the progestin action of desogestrel.
3. THIRD GENERATION CONTRACEPTIVES AND SIDE EFFECTS
Saudi Med J. 2011 Jan; 32: 23-6.
Desogestrel + ethinylestradiol versus levonorgestrel + ethinylestradiol. Which one has better affect on acne, hirsutism, and weight change.
Sanam M, Ziba O.
One-year clinical trial conducted on 100 healthy women who demonstrated that contraceptives based on desogestrel and ethinyl estradiol are safer than those containing levonorgestrel in terms of the incidence and severity of acne, hirsutism and weight changes.
Method of use and dosage
SECURGIN ® Ethylestradiol 20mcg and Desogestrel 150mcg Coated Tablets:
the intake of oral contraceptives such as SECURGIN ® should follow the classic cyclic pattern, characterized by the continuous administration of one tablet per day for 21 days, alternating with 7-day suspension periods, in which withdrawal bleeding should be observed, due to changes induced at the endometrial level.
The half-life of both active ingredients, estimated around 24 hours, allows to maintain maximum contraceptive coverage by simply taking one tablet a day at the same time, considering that already 36 hours after the last tablet there is a reduction in "contraceptive efficacy which gradually tends to disappear around the seventh day of suspension, in which physiological hormonal control is resumed.
Variations to the normal dosage schedule may be necessary in the course of particular pathologies, recent abortions or pregnancies, forgetfulness of daily intake or in the event of a change in the contraceptive used.
Warnings SECURGIN ® - Contraceptive Pill
Given the biological complexity of hormonal contraception and its potential long-term risks, before taking an oral contraceptive it would be necessary to undergo a careful medical examination to exclude the presence of conditions capable of increasing the incidence of the aforementioned. risks.
In fact, women suffering from current or previous cardiovascular and neoplastic diseases, liver and kidney diseases, neurological and psychiatric disorders, metabolic diseases such as diabetes and risk factors for cardiovascular diseases such as obesity or smoking should undergo periodic useful tests. to assess their state of health.
Especially in these cases the doctor / patient relationship is necessary in order to carefully consider the risk-benefit ratio of oral contraception, clarifying both the potential side effects and the first signs with which these occur, so that they can be recognized promptly and properly checked.
SECURGIN ® contains lactose so its intake in patients with lactase enzymatic deficiency, glucose / galactose malabsorption or lactose intolerance, could be associated with even serious gastrointestinal disorders.
PREGNANCY AND BREASTFEEDING
The absence of studies such as to fully characterize the safety profile of SECURGIN ® when taken during pregnancy and the scarce need to resort to a contraceptive method during the same period, do not allow the use of oral contraceptives during the gestational period.
Furthermore, the ability of the estrogens and progestogens contained in these drugs to permeate the breast filter and concentrate in the breast milk extends this contraindication also to the subsequent breastfeeding phase.
Interactions
The hepatic metabolism to which both ethinylestradiol and desogestrel are subjected significantly increases the risk of drug interactions capable of altering the pharmacokinetic properties of SECURGIN ® reducing its contraceptive efficacy.
More precisely, the simultaneous intake of metabolic inducers of citrochromial enzymes such as rifampicin, phenytoin, barbiturates, antiretrovirals, antibiotics, herbal remedies such as St. John's wort could increase the metabolism of the hormones contained in SECURGIN ® thus reducing blood concentrations and "biological efficacy.
Consequently, before taking any drug it would be advisable to seek the advice of your doctor and possibly resort to contraceptive methods of coverage.
Contraindications SECURGIN ® - Contraceptive Pill
SECURGIN ® is contraindicated in case of current or previous venous thrombosis, stroke, hypertension, metabolic diseases such as diabetes mellitus, hypertension and dyslipidemia, impaired liver and kidney function, malignant diseases, neuro-psychiatric disorders, motor disorders, undiagnosed gynecological diseases and in case of hypersensitivity to the active substance or to one of its excipients.
Undesirable Effects - Side Effects
Although third generation oral contraceptives have been designed to reduce some side effects of hormonal contraceptive therapy such as weight gain and skin disorders, taking SECURGIN ® has often been associated with side effects such as nausea, headaches, mood changes. , eye irritation, hemorrhagic spotting, increased breast tenderness and tenderness.
Particularly relevant from the clinical point of view, so much so in some cases that immediate discontinuation of the drug was required, were some long-term adverse reactions responsible for an increase in the frequency of arterial and venous thromboembolic accidents, hypertension and coronary heart disease, hyperlipidemia and cholestatic jaundice.
Note
SECURGIN ® can only be sold under medical prescription.
The information on SECURGIN ® - Contraceptive Pill published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
